According to the CHOIR (Correction of Hemoglobin and Outcomes in Renal Disease) and CREATE (Cardiovascular Risk Reduction by Early Anemia Treatment with Epoetin Beta) trials, the target range of HCT in uremic patients under HD is 30–36%, which is approximately equivalent to HB levels of 10–12 g/dL [21]. This evidence concerns the gene EPO and anemia (phenotype).